Aandeel OCGN OCUGEN, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Ocugen, Inc.

Aandelen

OCGN

US67577C1053

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 26-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
1,28 USD +8,47% Intraday-grafiek van Ocugen, Inc. -3,03% +122,61%
23/04 OCUGEN, INC. : Chardan Research ontvangt een koopadvies ZM
23/04 OCUGEN, INC. : Chardan Research bevestigt koopadvies ZM

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN
OCGN Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Ocugen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
OCUGEN TO PARTICIPATE IN FIRESIDE CHAT AT THE EMERGING GROWTH VIRTUAL HEALTHCARE EQUITY CONFERENCE, PRESENTED BY NOBLE CAPITAL MARKETS
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
Law Offices of Howard G. Smith Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ocugen, Inc. - OCGN
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers OCGN
  4. Nieuws Ocugen, Inc.
  5. Andere talen